Terence Kelly, PhD

Chief Executive Officer

Terence Kelly joined Perception in 2019 and has over 30 years of experience in the pharmaceutical industry in the US and Europe. After finishing postdoctoral studies in 1990, he worked as a medicinal chemist at Boehringer Ingelheim on projects in the areas of Immunology, Virology, CNS and Cardiovascular diseases. From 2002 to 2009 he led BI's medicinal chemistry department in the US, which included 145 scientists in the high throughput screening, computational chemistry, structural biology, combinatorial chemistry and medicinal chemistry groups.

He joined CoMentis in 2010 as Chief Scientific Officer and was responsible for the research and pre-clinical development activities in the portfolio of scientific programs, and the partnership with Astellas Pharmaceuticals.  Dr. Kelly was appointed by the board as President and CEO in November 2011 and led the development and implementation of corporate strategy, as well as fund-raising activities and partnering. 

In addition to operating roles, Terry has served as a Board Member (Director) at Cardax (CDXI) and AlloCyte AG.

Terry completed his BS degree in chemistry at Rensselaer Polytechnic Institute and his Ph.D. degree in chemistry at the University of Texas at Austin. He completed his postdoctoral work in natural products synthesis at Yale University. In addition to his scientific degrees and activities, Dr. Kelly also holds an MBA from New York University, Stern School of Business.